Compare FVCB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | OTLK |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.0M | 249.6M |
| IPO Year | 2018 | 2016 |
| Metric | FVCB | OTLK |
|---|---|---|
| Price | $17.54 | $1.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $2.50 |
| AVG Volume (30 Days) | 256.4K | ★ 22.3M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | 47.56 | ★ 55.91 |
| EPS | ★ 0.35 | N/A |
| Revenue | $1,781,000.00 | ★ $8,146,123.00 |
| Revenue This Year | $13.83 | $1,430.98 |
| Revenue Next Year | $7.45 | $173.23 |
| P/E Ratio | $49.40 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $11.74 | $0.16 |
| 52 Week High | $17.75 | $3.39 |
| Indicator | FVCB | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 72.44 | 75.78 |
| Support Level | $15.34 | $1.60 |
| Resistance Level | N/A | $2.09 |
| Average True Range (ATR) | 0.35 | 0.22 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 87.74 | 88.79 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.